GENUS AIDING BLUE-CHIP COMPANIES: Successful FDA approval propels Genus' animal genetics company, extending winning streak for significant corporations.
Fresh Take:
Stock market buzzes in London, as FTSE 100 records a 13-day winning streak despite a downturn in the US economy. Genus, a genetics firm listed on the FTSE 250, witnessed a significant surge in its shares - a whopping 16.1% jump! This leap was triggered by the approval of a key product from the US Food and Drug Administration (FDA).
The approved product is none other than Genus' ingenious PRRS Resistant Pig (PRP) gene edit. Designed to furnish pigs with immunity against porcine reproductive and respiratory syndrome (PRRS), a disease causing extensive respiratory issues, reproductive failures, and premature deaths in swine, this innovation is primed to make a substantial impact in the swine industry[1][2][5].
The PRP gene edit allows genetically-engineered pigs to enter the U.S. food supply chain, signifying a significant leap towards commercialization. This project zeroes in on editing genes to counteract PRRS virus strains plaguing pigs worldwide[5].
Other market players also made waves. Hip replacement maker Smith & Nephew saw a 5.8% growth, thanks to better-than-expected 3.1% increase in first-quarter revenues that offset the impact of tariffs worth up to £15 million[3]. Meanwhile, miner Glencore dropped 7.4% after reporting a grim 30% fall in first-quarter copper production[3].
Taylor Wimpey, a housing company, expects lower profit margins in the first half of 2025, due to lower selling prices and escalating builder inflation[3]. Shares experienced a minor loss as a result, shedding 0.8%[3].
Related Articles:
Previous * Next* Aston Martin cuts US exports as tariffs batter car industry: * Labour's postal sell-out: Did we learn nothing from the...
Share this article
HOW THIS IS MONEY CAN HELP
- Learning the tricks to picking the top (and cost-effective) stocks and shares Isa and the ideal DIY investing account
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Take a PeekTake a Peek### Hargreaves Lansdown
Hargreaves Lansdown
Take a PeekTake a Peek### interactive investor
interactive investor
Take a PeekTake a Peek### InvestEngine
InvestEngine
Take a PeekTake a Peek### Trading 212
Trading 212
Take a PeekTake a PeekAffiliate links: Should you opt for a product, This is Money might earn a commission. These deals are meticulously handpicked by our editorial team, as we consider them noteworthy. This doesn't hamper our editorial independence.
Compare the Best Investing Account for You
- Highlighting the FTSE 100's 13-day winning streak in London's stock market, personal-finance enthusiasts might find it intriguing to investigate the current state of investing in business sectors such as finance and technology.
- The approval of Genus' PRRS Resistant Pig (PRP) gene edit by the US Food and Drug Administration has triggered a significant 16.1% surge in the firm's stocks, showcasing the potential impact of innovative gene editing in the swine industry and the world of finance.
- While Genus and other market players like Smith & Nephew and Glencore make headlines, Taylor Wimpey anticipates lower profit margins in the first half of 2025 due to builder inflation and lower selling prices, signaling potential concerns for personal-finance investors in the housing sector.
- For those interested in the world of stocks and shares, This is Money offers valuable advice on how to pick top and cost-effective stocks and shares for your DIY investing account.
- When choosing an investing platform, consider options such as AJ Bell, Hargreaves Lansdown, interactive investor, InvestEngine, and Trading 212 – all of which provide significant insights into the current state of the market and investment opportunities for personal-finance management.
